A large prospective analysis of data from the UK Women’s Cohort Study found an association between red meat consumption and distal colon disease risk.
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable.
The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.
The combination of the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib yielded improved progression-free survival over vemurafenib in patients with advanced BRAF V600–mutant melanoma.
A phase III study by Dr. Robert Motzer and colleagues in NEJM found significantly higher OS and ORRs with the immunotherapy combination.
The combination of nivolumab with an interleukin-15 agonist was well tolerated with no dose-limiting toxicities in patients with metastatic non–small-cell lung cancer.
Three year OS was significantly worse compared with the general population, with a persistent risk for relapse.
Pembrolizumab offered stable or improved measures of global health status and quality of life compared with chemotherapy in patients with previously treated advanced urothelial cancer.
Antibody-mediated, immunotherapeutic strategies targeting survivin, a key cancer-related protein, may offer benefit in a variety of cancers.
Follicular large cleaved cell lymphoma is frequently misclassified, according to researchers.